Skip to main content
Article thumbnail
Location of Repository

Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial

By K.R. Lees, A. Davalos, S.M. Davis, H.-C. Diener, J. Grotta, P. Lyden, A. Shuaib, T. Ashwood, H.G. Hardemark, W. Wasiewski, U. Emeribe and J.A. Zivin

Abstract

<p><b>Background and Purpose:</b> NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from ischemic stroke. We conducted analyses on additional end points and sensitivity analyses to confirm our findings.</p>\ud \ud <p><b>Methods:</b> We randomized 1722 patients with acute ischemic stroke to a 72-hour infusion of placebo or intravenous NXY-059 within 6 hours of stroke onset. The primary outcome was disability at 90 days, as measured by the modified Rankin Scale (mRS), a 6-point scale ranging from 0 (no residual symptoms) to 5 (bed-bound, requiring constant care). Additional and exploratory analyses included mRS at 7 and 30 days; subgroup interactions with final mRS; assessments of activities of daily living by Barthel index; and National Institutes of Health Stroke Scale (NIHSS) neurological scores at 7 and 90 days.</p>\ud \ud <p><b>Results:</b> NXY-059 significantly improved the distribution of the mRS disability score compared with placebo at 7, 30, and 90 days (Cochran-Mantel-Haenszel test P=0.002, 0.004, 0.038, respectively; 90-day common odds ratio 1.20; 95% CI, 1.01 to 1.42). The benefit was not attributable to any specific baseline characteristic, stratification variable or subgroup interaction. Neurological scores were improved at 7 days (odds ratio [OR], 1.46; 95% CI, 1.13, 1.89; P=0.003) and the Barthel index was improved at 7 and 30 days (OR, 1.55; 95% CI, 1.22, 1.98; P&#60;0.0001; OR, 1.27; 95% CI, 1.01, 1.59; P=0.02).</p>\ud \ud <p><b>Conclusions:</b> NXY-059 within 6 hours of acute ischemic stroke significantly reduced disability. Benefit on neurological scores and activities of daily living was detectable early but not significant at 90 days; however, our trial was underpowered to measure effects on the neurological examination. The benefit on disability is not confounded by interactions and is supported by other outcome measures.</p

Publisher: American Heart Association
Year: 2006
OAI identifier: oai:eprints.gla.ac.uk:21525
Provided by: Enlighten

Suggested articles

Citations

  1. (2004). ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. doi
  2. (2000). Categorical Data Analysis using the SAS system, 2nd edition,
  3. (2001). Committee for Proprietary Medicinal Products (CPMP). Points to consider on clinical investigation of medicinal products for the treatment of acute stroke. The European Agency for the Evaluation of Medicinal Products. doi
  4. for the Stroke Therapy Academic Industry Roundtable. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. doi
  5. (1965). Functional evaluation: the Barthel Index. Md Med J.
  6. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. doi
  7. Group. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. doi
  8. Hardemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. doi
  9. International Trial Steering Committee and Investigators. Comparison of the National Institutes of Health Stroke Scale with disability outcome measures in acute stroke trials. doi
  10. Interobserver agreement for the assessment of handicap in stroke patients. doi
  11. Measurements of acute cerebral infarction: a clinical examination scale. doi
  12. Multiple testing: multiple comparisons and multiple endpoints. doi
  13. (2003). Nitrones as neuroprotective agents in cerebral ischemia with particular reference to NXY-059. Pharmacol Ther. doi
  14. (2003). Odergren T; SA-NXY-0004 Investigators. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke. doi
  15. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. doi
  16. Strengthening acute stroke trials through optimal use of disability endpoints. doi
  17. (2006). Stroke Data Bank Collaborators. Assessment of functioning and disability after ischemic stroke. doi
  18. (1995). The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. doi
  19. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.